Cardiovascular diseases (CVDs) remain the leading cause of global morbidity and mortality, with reported cases having doubled since 1990. Today, CVDs account for one in three deaths worldwide, representing 32% of total global mortality, with heart attacks and ischemic strokes responsible for approximately 85% of these outcomes. The rising burden is strongly associated with population aging and an increasing prevalence of lifestyle-related risk factors, including hypertension, obesity, and diabetes. Economically, the impact is profound—annual CVD-related healthcare expenditures in the United States are projected to reach USD 1.49 trillion by 2050, while costs across the European Union have already exceeded USD 326.1 billion (2024).

Advancements in gene editing, biomarker discovery, digital biomarkers, and digital health platforms are accelerating the shift toward precision cardiology, enabling more personalized and predictive patient management. Digital technologies such as digital twins are transforming diagnostic accuracy and prognostic modeling, allowing clinicians to simulate treatment pathways and deliver tailored interventions. The increasing adoption of mechanistic modeling and multiscale simulations is helping define optimal therapeutic strategies, underscoring their role in propelling precision cardiology forward.

• How can your team strengthen evidence generation, promote equitable access, and achieve growth within the clinical care continuum?
• Why are solutions focused on dose optimization, reduced medication burden, and episodic risk management gaining traction, and what steps can healthcare providers take to improve outcomes while minimizing treatment costs?
• Which pharmaceutical companies are forming strategic partnerships with academic institutions, professional societies, government bodies, and payer organizations for growth?